Acuity is developing treatments for age-related macular degeneration (AMD) and diabetic retinopathy (DR), two of the leading causes of adult blindness in the developed world. Acuity submitted the first-ever IND to FDA to initiate human trials for a short interfering RNA (siRNA) therapeutic in August 2004. Acuity plans to advance its lead compound, Cand5, a small interfering RNA (siRNA) drug, into Phase II clinical trials for AMD in late 2005. Acuity was the first-ever company to administer an investigational siRNA drug to human patients.
Please check Acuity Pharmaceuticals for more information.